Targets › XPO1
2 programs from 2 companies in 50 trials: 28 Phase 2, 19 Phase 1, 3 Phase 3; Oncology, Hematology; next expected readout Dec 2026.
Mediates the nuclear export of cellular proteins (cargos) bearing a leucine-rich nuclear export signal (NES) and of RNAs. In the nucleus, in association with RANBP3, binds cooperatively to the NES on its target protein and to the GTPase RAN in its active GTP-bound form (Ran-GTP). (UniProt, O14980)
Open in Phaseline: the race on XPO1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Karyopharm Therapeutics | Selinexor (KPT-330) Exportin-1 inhibitor | XPO1 | Phase 3 | Endometrial Cancer; Myelofibrosis; Diffuse Large B-cell Lymphoma; Relapsed/Refractory Diffuse Large B-cell Lymphoma … | Dec 2026 |
| Vanderbilt-Ingram Cancer Center | Eltanexor Nuclear export inhibitor; traps tumor suppressing proteins within the cell | XPO1 | Phase 1 | Relapsed Myelodysplastic Syndrome | Feb 2027 |
Multiple Myeloma (6) Myelofibrosis (5) Multiple Myeloma in Relapse (2) Endometrial Cancer (1) Diffuse Large B-cell Lymphoma (1) Relapsed/Refractory Diffuse Large B-cell Lymphoma (1) Multiple Myeloma, Refractory (1) Smoldering Multiple Myeloma (1) Refractory Multiple Myeloma (1) nk/T-cell Lymphoma (1) Lymphohistiocytosis (1) Diffuse Large B Cell Lymphoma (1)
small molecule (2)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.